Psilocybin-assisted Therapy for Treatment of Alcohol Use Disorder

Phase 2 Completed 60 enrolled Anders Fink-Jensen, MD, DMSci The Neurobiology Research Unit at Copenhagen University Hospital Rigshospitalet · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Note: The trial is only eligible for citizens of Denmark. The purpose of this project is to assess the treatment efficacy of a single high dose of psilocybin administered within a protocol of psychological support to patients diagnosed with alcohol use disorder (AUD).

Timeline

Start: 2023-09-01
Primary completion: 2025-12-22
Completion: 2025-12-22

Publications

Jensen ME, Stenbaek DS, Juul TS, Fisher PM, Ekstrom CT, Knudsen GM, Fink-Jensen A. Psilocybin-assisted therapy for reducing alcohol intake in patients with alcohol use disorder: protocol for a randomised, double-blinded, placebo-controlled 12-week clinical trial (The QUANTUM Trip Trial). BMJ Open. 2022 Oct 14;12(10):e066019. doi: 10.1136/bmjopen-2022-066019.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Psilocybin	Other / unclassified	25 mg	—

Psilocybin-assisted Therapy for Treatment of Alcohol Use Disorder

Summary

Timeline

Publications

Drugs

Indications